Duke Cunningham Can't Have Gun
Don Bauder 9:47 p.m., May 25
Biotech Amylin stock is up 18.04% to $14.33 at mid-day Monday (Jan. 30), following Food & Drug Administration approval for U.S. marketing of Bydureon, a once-weekly version of Amylin's diabetes shot.
This was the third try with the FDA. Amylin is working with Alkermes on the drug.
Now, takeover sharks may be circling Amylin, according to Bloomberg News. Those rumors may also be boosting the stock.
Comments
Visduh Jan. 31, 8:25 a.m.
It could be wonderful news for long-suffering Amylin shareholders, but not for Amylin employees (unless, of course, they have stock options.)
dbauder Jan. 31, 3:55 p.m.
Yes, Visduh, those Amylin shareholders have certainly been longsuffering. There were times when the company was right on the edge of extinction. Best, Don Bauder
Sign in to comment
Or login with:
OpenID